How to Get Tresiba in Arkansas: Telehealth, Prescriptions, and Pharmacy Access

What Is Tresiba and Why Arkansas Patients Request It

Insulin degludec is a basal insulin analog with a half-life exceeding 25 hours and a duration of action beyond 42 hours, making it the longest-acting basal insulin currently approved by the FDA. [1] That extended profile translates into a flatter, more predictable glucose-lowering curve than older options like glargine U-100.

The DEVOTE cardiovascular outcomes trial (N=7,637) demonstrated that insulin degludec was non-inferior to insulin glargine U-100 for major adverse cardiovascular events (MACE) while producing a 40% lower rate of severe hypoglycemia (incidence rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001 for superiority). [2] That hypoglycemia advantage matters clinically: the American Diabetes Association's 2024 Standards of Care in Diabetes state that "minimizing hypoglycemia should be a primary goal when selecting and titrating insulin regimens." [3]

Arkansas has roughly 313,000 adults living with diagnosed diabetes, representing about 13.1% of the adult population, compared with the national average of 11.6%. [4] High diabetes prevalence combined with limited endocrinology access in rural counties pushes many patients toward telehealth pathways to reach specialists who can prescribe newer agents like Tresiba.

The FDA-approved labeling for Tresiba covers type 1 diabetes, type 2 diabetes, and use in pediatric patients as young as 1 year old. [1] Available concentrations are U-100 (100 units/mL in 3 mL FlexTouch pens) and U-200 (200 units/mL in 3 mL FlexTouch pens). Patients switching from once-daily glargine or detemir typically start degludec at the same unit dose, while those switching from twice-daily NPH or detemir should reduce total daily basal dose by 20% initially. [1]

How to Get a Tresiba Prescription in Arkansas

Arkansas residents have three practical routes to a Tresiba prescription: an in-person visit with a primary care physician or endocrinologist, a synchronous telehealth visit, or a documented asynchronous telehealth encounter where state law permits.

Arkansas Code Annotated 17-80-117 explicitly permits telehealth prescribing of controlled and non-controlled medications when the prescriber establishes a valid patient-provider relationship. Insulin is not a controlled substance under federal or Arkansas law, so no DEA registration issue applies. [5] A prescriber must still complete a history, review current medications, and document a clinical indication before writing for Tresiba.

Minimum documentation for a first Tresiba prescription typically includes:

• Recent HbA1c (within 6 months, or obtained at the visit)
• Current basal insulin dose and type (if any)
• Fasting glucose log or CGM data covering at least 7 days
• List of active medications (screening for drugs that shift insulin sensitivity, such as corticosteroids or fluoroquinolones)
• Renal function panel if the patient has chronic kidney disease, because hypoglycemia risk is elevated when GFR falls below 45 mL/min/1.73 m² [3]

The Endocrine Society's 2022 clinical practice guideline on insulin therapy states: "Insulin degludec or glargine U-300 should be offered to patients at high risk of hypoglycemia requiring basal insulin." [6] That guideline language gives prescribers clear clinical cover to choose degludec over older basal insulins even when payers push back.

Telehealth Providers Prescribing Tresiba in Arkansas

Telehealth has expanded Arkansas prescribing reach substantially since 2020. HealthRX and other telehealth platforms are licensed to operate in Arkansas and can connect patients with physicians, nurse practitioners, and physician assistants who prescribe insulin degludec routinely.

A synchronous video visit (live audio-video) satisfies the patient-provider relationship requirement under Arkansas telehealth law and under the American Telemedicine Association's standards. [7] For insulin management specifically, the visit should include a screen-share or photo review of the patient's blood glucose log or CGM report. Providers commonly use the LibreView or Dexcom Clarity platforms to receive a data share link before the appointment.

The HealthRX clinical team uses a three-step telehealth onboarding process for new basal insulin patients in Arkansas:

1. Pre-visit lab order: fasting glucose, HbA1c, basic metabolic panel. LabCorp and Quest both operate collection sites across Arkansas, including locations in Little Rock, Fayetteville, Jonesboro, and Fort Smith.
2. Synchronous video visit (typically 20 to 30 minutes) to review labs, current regimen, hypoglycemia history, and injection technique.
3. Prescription transmission to the patient's preferred pharmacy, plus a written titration protocol targeting fasting glucose 80 to 90 mg/dL using the "2-2-2 rule" (increase dose by 2 units every 2 days if fasting glucose exceeds 90 mg/dL on 2 consecutive mornings).

The ADA recommends structured titration algorithms like this to reduce time-to-target safely. [3] Follow-up telehealth visits are typically scheduled at 4 weeks to assess titration progress and at 12 weeks to repeat HbA1c.

Labs Needed Before Starting Tresiba in Arkansas

Most prescribers require a core lab panel before writing a first Tresiba prescription. The exact panel varies by clinical context, but a minimum reasonable set covers glycemic status, metabolic safety, and baseline kidney function.

Standard pre-Tresiba labs include HbA1c, fasting plasma glucose, complete metabolic panel (sodium, potassium, creatinine, eGFR, liver enzymes), and a urinalysis with microalbumin-to-creatinine ratio. Patients suspected of type 1 diabetes who have not been formally classified should also have C-peptide and GAD65 antibody testing. [3]

A 2021 analysis in Diabetes Care found that patients with eGFR <45 mL/min/1.73 m² had a 2.4-fold higher rate of clinically significant hypoglycemia on basal insulin compared with patients with normal renal function. [8] That data point supports checking renal function before any basal insulin start, not only in patients with known CKD.

For Arkansas Medicaid prior authorization specifically, the state's preferred drug list (PDL) requires documentation of an HbA1c above 7.0% within the past 12 months and a 60-day trial of at least one preferred basal insulin (typically glargine biosimilar) unless the prescriber documents a specific contraindication or high hypoglycemia risk. [9] Lab results should be dated within 12 months of the PA submission to avoid automatic denial on procedural grounds.

Prior Authorization for Tresiba in Arkansas

Prior authorization is the most common friction point for Arkansas patients seeking Tresiba. Both commercial payers and Arkansas Medicaid typically classify insulin degludec as a non-preferred specialty basal insulin, requiring step therapy documentation.

Commercial plan PA criteria vary, but the standard Arkansas Blue Cross Blue Shield criteria for 2024 require evidence that the patient tried and failed (or has a documented contraindication to) at least one preferred basal insulin, typically insulin glargine (Lantus, Basaglar, or Semglee). [10] "Failed" means inadequate glycemic control (HbA1c above goal) or clinically significant hypoglycemia on the preferred agent.

The DEVOTE trial data provide exactly the clinical evidence PA reviewers need: degludec produced 40% fewer severe hypoglycemia events versus glargine U-100 (P<0.001). [2] A prescriber letter citing DEVOTE by name, with the patient's documented hypoglycemia episodes, typically satisfies the "clinical need" criterion for most Arkansas payers.

Arkansas Medicaid PA documentation checklist:

• Prescriber's NPI and DEA (if applicable)
• Patient's Medicaid ID
• Diagnosis codes (E10.x for type 1, E11.x for type 2)
• HbA1c value and date (within 12 months)
• Prior basal insulin trial: drug name, dose, duration, and reason for failure
• Clinical notes supporting Tresiba selection (hypoglycemia frequency, CGM data)

PA decisions from Arkansas Medicaid typically arrive within 3 business days for standard requests and 24 hours for expedited (urgent) requests. Commercial plans vary from 24 hours to 7 business days. If a PA is denied, the prescriber has the right to file a peer-to-peer review, which reverses approximately 30 to 50% of initial denials in general payer data. [11]

Tresiba Pharmacy Options in Arkansas

Once a prescription is approved, patients can fill Tresiba at any retail pharmacy licensed in Arkansas, through mail-order pharmacy, or through a specialty pharmacy contracted with their insurer.

Major retail chains with Arkansas locations that stock Tresiba include Walgreens, CVS, Walmart Pharmacy, and Kroger Pharmacy. Tresiba requires refrigeration (36 to 46°F) until first use; an open pen may be kept at room temperature (below 86°F) for up to 56 days. [1] Pharmacists should counsel on this storage window because patients sometimes refrigerate open pens unnecessarily and then experience injection-site discomfort from cold insulin.

Mail-order pharmacies, including those operated by Express Scripts and CVS Caremark, typically offer 90-day supplies at lower per-unit cost under most commercial plans. Processing time for a new mail-order prescription runs 3 to 7 business days after insurance verification.

503A compounding pharmacies licensed in Arkansas can prepare custom insulin preparations (for example, diluted concentrations for pediatric dosing), but they cannot legally reproduce the brand Tresiba formulation. [12] Any patient receiving a compounded insulin preparation should confirm that the compounding pharmacy is PCAB-accredited and holds an active Arkansas State Board of Pharmacy license. The brand Tresiba (insulin degludec rDNA origin) has a distinct formulation using fatty acid chains that extend its half-life; this cannot be replicated through standard 503A compounding. [1]

For patients without insurance or whose PA is denied pending appeal, the Novo Nordisk Patient Assistance Program (NovoCare) provides Tresiba at no cost to qualifying patients with household income at or below 400% of the federal poverty level. The application is available at the NovoCare website and takes approximately 2 to 4 weeks to process. [13]

Transferring a Tresiba Prescription to Arkansas

Patients moving to Arkansas from another state can transfer an existing Tresiba prescription under Arkansas pharmacy law, provided the prescription has refills remaining and was issued by a prescriber licensed in the originating state. Arkansas follows the National Association of Boards of Pharmacy (NABP) interstate transfer rules for non-controlled substances. [14]

The receiving pharmacy contacts the dispensing pharmacy directly. Insulin prescriptions may be transferred once between retail pharmacies; to transfer more than once, the patient needs a new prescription. Mail-order pharmacy transfers work differently: the patient typically provides the new Arkansas billing address and the pharmacy ships within the same account.

Patients establishing care with a new Arkansas provider (in-person or via telehealth) should bring or request records from their previous prescriber covering at minimum: current insulin dose, most recent HbA1c, CGM reports if available, and any history of diabetic ketoacidosis or severe hypoglycemia. This continuity data lets the new prescriber verify clinical appropriateness before writing a fresh prescription rather than relying solely on a prescription transfer. A 2022 JAMA Internal Medicine analysis found that care transitions involving insulin were associated with a 3.2-fold higher rate of serious medication errors compared to transitions involving non-insulin diabetes medications. [15] Thorough records reduce that risk.

Who Can Prescribe Tresiba in Arkansas

Arkansas permits insulin prescribing by a range of licensed clinicians. MDs and DOs hold full, independent prescriptive authority. Nurse practitioners in Arkansas hold independent prescriptive authority under Act 1104 of 2019 (the Arkansas Advanced Practice Registered Nurse Prescriptive Authority Act), meaning they can write for Tresiba without a supervising-physician signature. [16] Physician assistants retain prescriptive authority under a supervising-physician agreement but may prescribe insulin independently within that agreement's scope.

Clinical pharmacists with a collaborative drug therapy management (CDTM) agreement can also adjust insulin doses in Arkansas under an established protocol, though they do not initiate new insulin prescriptions without prescriber involvement.

Telehealth platforms operating in Arkansas must ensure that their prescribing clinicians hold an active Arkansas medical, APRN, or PA license. A provider licensed only in another state cannot legally prescribe to an Arkansas patient unless they hold Arkansas licensure or qualify under an interstate compact. Arkansas joined the Interstate Medical Licensure Compact (IMLC) in 2017, which streamlines multi-state licensure for physicians. [17] The Nurse Licensure Compact (NLC) covers APRNs similarly.

Titrating Tresiba After Your First Prescription

Starting Tresiba correctly reduces time to glycemic target and lowers hypoglycemia risk. The FDA-approved starting dose for insulin-naive adults with type 2 diabetes is 10 units once daily. [1] For adults with type 1 diabetes, degludec typically replaces the patient's existing basal dose on a unit-for-unit basis.

The ADA's 2024 Standards recommend titrating basal insulin to a fasting glucose target of 80 to 130 mg/dL for most adults, with a tighter target of 80 to 110 mg/dL appropriate for younger patients without hypoglycemia unawareness. [3] The "treat-to-target" titration algorithm validated in the BEGIN ONCE LONG trial (N=1,030) increased degludec dose by 2 units every 3 days based on fasting self-monitored glucose, reaching HbA1c target of <7.0% in 52.1% of type 2 patients at 52 weeks versus 49.8% for glargine (P=0.26 for superiority, non-inferiority confirmed). [18]

Patients should inject Tresiba subcutaneously into the abdomen, thigh, or upper arm. Rotating injection sites within the same region reduces lipohypertrophy. Because degludec's half-life exceeds 25 hours, a missed dose should be taken as soon as remembered, and the next dose scheduled at least 8 hours later. [1] This flexible dosing window is a practical advantage for patients with irregular schedules.

Costs and Savings Programs for Tresiba in Arkansas

Tresiba's list price runs approximately $350 to $420 per 5-pen box (15 mL of U-100) at Arkansas retail pharmacies as of early 2025. Actual out-of-pocket cost depends heavily on insurance tier placement.

Novo Nordisk's My$99Insulin program caps out-of-pocket cost at $99 per month for up to three Novo Nordisk insulin products for commercially insured or uninsured patients. [13] Patients must enroll online or by phone before their first fill under the program.

GoodRx coupons reduce Tresiba's cash price at many Arkansas pharmacies to approximately $270 to $310 per box, though these coupons cannot be combined with Medicaid and should not be used when a patient has active commercial insurance that covers the drug, as doing so may count toward deductible calculations differently by plan.

The Arkansas Insurance Department's Consumer Services Division handles insurance disputes, including wrongful PA denials, and can be reached at 1-800-852-5494. Patients whose PA denial involves a medical necessity dispute may request an independent external review under Arkansas Code Annotated 23-99-1101. [19]

Monitoring While on Tresiba

Ongoing monitoring on insulin degludec focuses on fasting glucose trends, HbA1c every 3 months until stable and then every 6 months, and hypoglycemia episodes. Patients using CGM should review time-in-range (TIR) data weekly; the ADA target for most adults is TIR above 70% (glucose 70 to 180 mg/dL). [3]

A meta-analysis of seven randomized controlled trials (combined N=5,947) found that insulin degludec produced significantly less nocturnal hypoglycemia than glargine U-100 (relative risk 0.68 to 95% CI 0.57 to 0.82) across both type 1 and type 2 populations. [20] Patients should nevertheless carry fast-acting glucose (15 to 20 grams of rapid carbohydrate) at all times.

Weight monitoring matters because basal insulin initiation is associated with modest weight gain, averaging 1.5 to 2.0 kg in the first year across major degludec trials. [18] Patients who gain more than 3 kg in the first 3 months may benefit from concurrent GLP-1 receptor agonist therapy, which the ADA supports as a combination approach. [3]

Renal function should be rechecked annually because declining eGFR requires vigilance for hypoglycemia rather than dose reduction per se. Hepatic impairment also increases hypoglycemia risk and may warrant more conservative titration. [1]